Latest research on Velcade

Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Velcade side effects

The CCK8 assay showed that cell viability was increased by ectopic expression of miR-30b-5p or miR-30c-5p in both HepG2 and MDA-MB-453 cells; and conversely, the cell viability was decreased by inhibition of miR-30b-5p or miR-30c-5p with specific inhibitor both under the basal cell culture condition and after PS-341 treatment (50 nM, 24 h) (Fig. 2A). [source, 2016]
Consistent with fluorescence microscopic analysis, apoptosis analysis by flow cytometry showed that after treatment with PS-341, the percentage of apoptotic and necrotic cells decreased in HepG2 and MDA-MB-453 cells overexpressing either of these miRs, while increased in cells with inhibition of either of these miRs (Fig. 2C). [source, 2016]
How to cite this article: Jiang, L. et al. A microRNA-mediated decrease in eukaryotic initiation factor 2α promotes cell survival during PS-341 treatment. [source, 2016]
The combination of Velcade plus tPA resulted in increased levels of miR-l46a on cerebral endothelial cells, which express TLRs, and outcomes were associated with reduced expression of vascular interleukin-1 receptor-activated kinases 1 (116). [source, 2015]
Because the majority of cancer cells exhibit higher levels of proteasome activity, they are more prone to the negative effects of proteasome inhibitors such as bortezomib (BTZ, Velcade), a reversible proteasome inhibitor that has been approved by the FDA to treat subtypes of hematological malignancies including plasma cell myeloma and mantle cell lymphoma [24, 27]. [source, 2015]
In the last decade, the addition of novel agents such as the proteasome inhibitor bortezomib (Velcade ®) to the regimen has resulted in a substantial increase in the number of patients responding to therapy[2]. [source, 2015]
As expected, challenge with the proteasome inhibitor Velcade, a potent proteotoxic stressor, markedly increased whole-body luciferase activities. [source, 2015]
In the context reviewed here, bortecimib can have serious side effects on the nervous system (see Velcade EMA/27714/2015) such as posterior reversible encephalopathy syndrome, autonomic neuropathy (damage to nerves controlling organs such as the bladder, eyes, gut, heart, and blood vessels), or more commonly peripheral neuropathy (nerve damage in hands and feet). [source, 2015]
Gazzerro et al. (2010) suggested that treatment with Velcade (0.8 mg/Kg) over a 2-week period reduced muscle degeneration and necrotic features, and increased muscle size (gastrocnemius and diaphragm), in mdx muscle fibers. [source, 2014]
More recently, through a series of elegant experiments, it was shown that in Velcade resistant patients, there is an increase in XBP1 low expressing MPCs which share common genetic changes as the myeloma plasma cells. [source, 2014]